Psyence Biomedical Announces $25M Stock Sale Deal
PremiumCompany AnnouncementsPsyence Biomedical Announces $25M Stock Sale Deal
23d ago
Psyence Group provides update on Filament Health commercial licensing agreement
Premium
The Fly
Psyence Group provides update on Filament Health commercial licensing agreement
29d ago
Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Premium
Press Releases
Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
29d ago
Psyence Biomedical Confronts Nasdaq Compliance Challenge
PremiumCompany AnnouncementsPsyence Biomedical Confronts Nasdaq Compliance Challenge
2M ago
Psyence Biomedical Issues Convertible Security
Premium
Company Announcements
Psyence Biomedical Issues Convertible Security
2M ago
Psyence Biomedical Issues Convertible Note
Premium
Company Announcements
Psyence Biomedical Issues Convertible Note
3M ago
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
PremiumPress ReleasesPsyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
5M ago
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
Premium
Press Releases
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
5M ago
Psyence Group closes strategic restructuring on non-clinical business
Premium
The Fly
Psyence Group closes strategic restructuring on non-clinical business
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100